Investigators

The Clinical Trial,
Re-Imagined.

The leaps we’re helping to deliver in research and innovation that inform better patient outcomes wouldn’t be possible without our deep partnerships with researchers and clinicians across all sectors of the healthcare landscape including: university, pharma, community health, and more.

I-SPY Family of Trials

The I-SPY series of trials are changing the way new treatments are developed, helping make available new, better and more personalized treatments, faster.

I-SPY Trials

The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer , employing an 'adaptive' clinical trial model designed to increase trial efficiency by minimizing the number of participants and time required to evaluated an experimental agent.

Phase 1: Pre-ISPY

I-SPY Phase 1b is an open-label platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients.

I-SPY ARDS/COVID Expansion

This trial focuses on identifying agents that can reduce mortality and the need for, as well as the duration of, mechanical ventilation or advanced respiratory support in patients with Acute Respiratory Distress Syndrome (ARDS).

RECAST DCIS

Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer by evaluating three investigational endocrine therapy arms.

I-SPY 2 Data

Download all the latest data and findings from our ongoing I-SPY 2 trials.

Publications

Interested in QLHC related research? Find the links here.

Resources

A thorough collection of useful research and data resources.

I-SPY 2 Leadership

Meet the leading minds leading our innovative cancer trials.

Partner With Us

Discover all the ways leading research organizations are partnering with us to deliver faster innovations in research and patient therapies.

I-SPY Clinical Sites

A collaborative network of partners helping us change the game in cancer care.

News Coverage

A collection of announcements and press releases related to Investigators

I-SPY 2.2 is working. Why aren’t others replicating the design?

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery

Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.

Investigators

The Clinical Trial, Re-Imagined.

I-SPY Family of Trials

The I-SPY series of trials are changing the way new treatments are developed, helping make available new, better and more personalized treatments, faster.

I-SPY 2 Data

Publications

Resources

I-SPY 2 Leadership

Partner With Us

I-SPY Clinical Sites

A collaborative network of partners helping us change the game in cancer care.

News Coverage

A collection of announcements and press releases related to Investigators

Your financial support of any amount can help make a huge leap in our efforts to deliver personalized medicine for all.

Trials

Resources

Contact Us

Studies

Collaborations

Publications

Contact Us

Donate

Investigators Portal

Partnerships

One Source

Donate

Our Approach

QLHC in the News

Working at QLHC

Contact Us

Donate

The Clinical Trial,
Re-Imagined.

Your financial support of any amount can
help make a huge leap in our efforts to
deliver personalized medicine for all.